OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Confirmation of detection of Omicron variant
VISITECT® COVID-19 antigen test performs with the same high accuracy on the Omicron variant
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, has been notified by its technology partner Mologic Ltd ("Mologic") that data from analysis on clinical samples, as well as in-silico analysis, show that the Mologic Covios® Ag lateral flow test, performs with the same high accuracy on the Omicron variant as it does with existing known variants.
This is the same test that is manufactured and sold for professional use by Omega as the VISITECT® COVID-19 antigen test.
Colin King, CEO, Omega Diagnostics, said: "We are very pleased be in a position to confirm that the VISITECT® COVID-19 antigen test is able to equally detect the Omicron variant, as well as other existing variants. We remain encouraged by emerging commercial opportunities for our VISITECT® COVID-19 Antigen test that we expect to be unlocked following relevant approval under CTDA regulations and CE-marking for home-use."
Contacts:
Omega Diagnostics Group PLC |
www.omegadx.com |
Colin King, Chief Executive Officer |
via Walbrook PR |
Chris Lea, Chief Financial Officer |
|
|
|
finnCap Ltd |
Tel: 020 7220 0500 |
Geoff Nash/Edward Whiley (Corporate Finance) |
|
Alice Lane/ Charlotte Sutcliffe (ECM) |
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus |
Mob: 07980 541 893 |
Lianne Applegarth |
Mob: 07584 391 303 |
Sam Allen |
Mob: 07502 558 258 |
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.